Skip to main content

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

Active, not recruiting · Phase 3 · NCT05248646

Conditions: Immunoglobulin A Nephropathy

At a glance

Research payments reported, 2025
$986,657
U.S. investigators named
40
Sites paid
40
Planned or actual enrollment
530

About the trial

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Tested
Sibeprenlimab 400 mg (drug), Placebo (drug)
Dates
Started 2022-03-15; completion 2027-01-19
Results posted
Not yet

To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy

From ClinicalTrials.gov, last updated 2026-07-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Otsuka Pharmaceutical Development & Commercialization, Inc. reported $986,657 in research payments for this study in 2025 (55 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.